Drug intelligence / Profile preview

JJH201801

Development stage: Preclinical
Lead developer: Jiangsu Jibeier Pharmaceutical
Modality: Classical Binding Small Molecules → Small Molecules

Overview

JJH201801 is a preclinical-stage small molecule deuterated compound being developed by Jiangsu Jibeier Pharmaceutical for the treatment of cholecystitis and gallstones. Developed using the company's proprietary deuterated drug R&D technology platform, the compound aims to provide a novel therapeutic option for biliary diseases. While the specific biological target and mechanism of action remain undisclosed, the use of deuterium enrichment is typically intended to enhance the metabolic stability, safety, or efficacy profile of the drug candidate by utilizing the kinetic isotope effect.

Beyond the preview

Go deeper on JJH201801.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JJH201801.

Explore the full profile